CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPAR?), a nuclear receptor that regulates genes involved in bile acid and lipid metabolism and inflammation. CymaBay is currently conducting two Phase 3 studies of seladelpar, one in patients with primary biliary cholangitis (PBC) and the other in patients with nonalcoholic steatohepatitis (NASH). CymaBay is also developing arhalofenate, a potential treatment for gout. CymaBay Therapeutics is headquartered in Newark, California and can be reached at +1-510-293-8800 or www.cymabay.com.